Kathy S. Albain
Breast and lung oncologist who led the trials showing gene tests can guide chemotherapy decisions.
Medical oncologist who led SWOG 8814 (Oncotype DX in node-positive disease) and co-led RxPONDER, and chaired SWOG trials in stage III lung cancer.
Pages like this
not linked directly; found by shared links- PairingGene-expression assay → chemotherapy omission
Shares RxPONDER (SWOG S1007), TAILORx, Oncotype DX, HR-positive / HER2-negative breast cancer.
- IdeaA formal regulatory route for validating a biomarker on archived trial samples
Shares RxPONDER (SWOG S1007), TAILORx, Oncotype DX.
- InstitutionWinship Cancer Institute of Emory University
Shares RxPONDER (SWOG S1007), Oncotype DX, SWOG Cancer Research Network, HR-positive / HER2-negative breast cancer.
- InstitutionMontefiore Einstein Comprehensive Cancer Center
Shares TAILORx, Oncotype DX, HR-positive / HER2-negative breast cancer.
- PersonMariana Chavez-MacGregor
Shares SWOG Cancer Research Network, HR-positive / HER2-negative breast cancer.
- ProductMammaPrint (70-gene signature)
- PersonDawn L. Hershman
Shares SWOG Cancer Research Network, HR-positive / HER2-negative breast cancer.
- CompanyExact Sciences (Abbott)
Shares Oncotype DX, HR-positive / HER2-negative breast cancer.